ProCE Banner Activity

Optimal Treatment for Patients With Progressive RCC After 1 or More Previous Lines of Therapy

Slideset Download

Download these slides from a live webinar for the most recent data on the selection and sequencing of therapy for patients with advanced RCC after progression on first-line therapy.

Released: June 05, 2022

Expiration: June 04, 2023

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AVEO Pharmaceuticals, Inc.

Eisai Inc.

Exelixis

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Katy Beckermann, MD, PhD

Assistant Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Katy E. Beckermann, MD, PhD, has disclosed that she has received consulting fees from Aravive, AVEO, Bristol Myers Squibb, Exelixis, and Seagen and funds for research from Bristol Myers Squibb.